Dr. Thomas Grub has over 16 years of experience in the pharmaceutical industry, specializing in Global Pricing & Market Access. He currently serves as the Director of Global Pricing & Market Access at medac GmbH, where he has been leading the global strategy for market access, pricing, and health economics since September 2024. Prior to this role, he was the Senior Expert for Global Market Access and Health Economics at medac, where he played a pivotal role in developing global access strategies for a diverse range of therapeutic areas, including orphan drugs and immunotherapies.

Earlier in his career, Dr. Grub worked as Director of Global Market Access and Health Economics, where he built and led the Market Access function within the newly established corporate management division at medac. He has also held various roles in the pharmaceutical industry, including Senior Product Manager in dermatology at Schering Deutschland GmbH.

In addition to his corporate roles, Dr. Grub is actively involved in industry associations. He is the Vice Chair of the Value Added Medicines Sector Group of Medicines for Europe and represents EUCOPE in the WHO Europe Novel Medicines Platform.

Dr. Grub holds a Ph.D. in Chemistry from Rheinland-Pfälzische Technische Universität Kaiserslautern-Landau.

At medac group, we believe that health is humanity’s most valuable resource. Since 1970, our mission has been to improve patients’ quality of life worldwide by making the best medical treatments available. As a globally operating pharmaceutical company headquartered in Germany, we provide high-quality medical treatments for patients worldwide in 91 countries. With more than 2.000 employees we are committed to improving human health.   All our products are manufactured in Germany and other European countries to the highest standards, utilizing our own logistics center and production sites, and subsequently distributed worldwide.